CEDAR KNOLLS, N.J.,
Nov. 20, 2019 /PRNewswire/ -- MYOS
RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), an
advanced nutrition company and the owner of Fortetropin, a
proprietary bioactive composition made from fertilized egg yolk
that helps build lean muscle, announced today that an abstract
based on the results from a clinical trial evaluating the impact
of Fortetropin on the rate of muscle protein synthesis in older men
and women has been accepted for an oral presentation at the
upcoming International Conference on Frailty and Sarcopenia
Research ("ICFSR") that will take place in
Toulouse, France
(https://frailty-sarcopenia.com/) on March
11, 2020 at 12:15 pm.
The presentation, entitled "Effects of Fortetropin on the
Rate of Muscle Protein Synthesis in Older Men and Women: A
Randomized, Double-Blinded Control Study," will be given by
the Principal Investigator of the study, William J. Evans, Ph.D., Adjunct Professor of
Nutrition at the University of California,
Berkeley.
![(PRNewsfoto/MYOS RENS Technology) (PRNewsfoto/MYOS RENS Technology)](https://mma.prnewswire.com/media/656707/MYOS_RENS_Technology_Logo.jpg)
In this clinical study, 20 subjects, men and women 60 to 75
years of age, consumed either Fortetropin or a
macronutrient-matched placebo for 21 days along with daily doses of
a heavy water tracer. After 21 days, a muscle biopsy was collected
from each subject and analyzed to determine the average muscle
protein synthesis rate. For subjects who received Fortetropin, the
average muscle protein synthesis rate was significantly higher
compared to the placebo group.
Muscle loss represents one of the most important causes of
functional decline and loss of independence in older adults.
Age-related muscle loss (sarcopenia) is commonly observed in many
older adults and is also characterized by a decrease in the rate of
muscle protein synthesis. In addition, low muscle mass is
associated with increased risk of hip fracture and disability.
Fortetropin was shown to increase the average muscle protein
synthesis rate, providing the potential to improve muscle health
among older adults. There are very limited options available to
address age-related muscle loss. Geriatricians commonly manage this
through lifestyle interventions such as diet and exercise.
"This study shows Fortetropin's remarkable potential for
managing age-related muscle loss in older adults. The
ICFSR is the most important medical conference in the
world focused on highlighting advances in sarcopenia
research. We feel truly honored that research highlighting
the clinical impact of Fortetropin will be presented for the first
time at this meeting. The results from this clinical study
will form the cornerstone of MYOS' 'Healthy Aging' Business,"
commented Joseph Mannello, Chief Executive Officer of
Myos.
"I look forward to sharing the exciting results from this
clinical study with the scientific community at the ICFSR meeting,"
commented Dr. Evans, a key opinion leader in sarcopenia.
"Fortetropin clearly has a robust effect on the rate of muscle
protein synthesis in older adults. It is rare for a nutrition
product to show such a consistent and positive effect. We look
forward to continued scientific collaboration with MYOS."
About MYOS RENS Technology Inc.
MYOS RENS Technology
Inc. (MYOS), "The Muscle Company®," is a Cedar Knolls, NJ-based advanced nutrition
company that develops and markets products that improve muscle
health and performance. MYOS is the owner of
Fortetropin®, a fertilized egg yolk-based product
manufactured via a proprietary process to retain and optimize its
biological activity. Fortetropin has been clinically shown to
increase muscle size, lean body mass and reduce muscle atrophy.
MYOS believes Fortetropin has the potential to redefine existing
standards of physical health and wellness. For more information,
please visit www.myosrens.com.
About Myos Canine Muscle Formula®
Myos
Canine Muscle Formula (Regular and Veterinarian Strength) is
an advanced veterinary health supplement to support muscle health
in dogs, featuring Fortetropin as the active ingredient.
Fortetropin is made through a patented process that maintains the
vital nutrients of fertilized egg yolks to help build more lean
muscle and decrease muscle loss. For more information, please
visit www.myospet.com.
About Yolked®
Yolked is an NSF
Certified for Sport® all-natural sports nutrition
product designed to work in conjunction with your protein of choice
to help your body utilize that protein more efficiently. Its key
ingredient, Fortetropin, is made through a patented process
that maintains the vital nutrients of fertilized egg yolks to help
build more lean muscle and decrease muscle loss. For more
information, please visit www.yolked.com.
Forward-Looking Statements
Any statements in
this release that are not historical facts are forward-looking
statements. Actual results may differ materially from those
projected or implied in any forward-looking statements. Such
statements involve risks and uncertainties, including but not
limited to those relating to product and customer demand, market
acceptance of our products, the ability to create new products
through research and development, the successful results of
strategic initiatives, the success of our products,
including Qurr®, Yolked®,
MYOS Canine Muscle Formula®, and MYOS
Enteral Nutrition Formula™, the success of our
research and development, the results of the clinical evaluation
of Fortetropin® and its effects, the
ability to enter into new partnership opportunities and the success
of our existing partnerships, the ability to generate revenue and
cash flow from sales of our products, the ability to increase our
revenue and gross profit margins, the ability to achieve a
sustainable, profitable business, the effect of economic
conditions, the ability to protect our intellectual property
rights, competition from other providers and products, the
continued listing of our securities on the Nasdaq Stock Market,
risks in product development, our ability to raise capital to fund
continuing operations, and other factors discussed from time to
time in our filings with the Securities and Exchange
Commission. We undertake no obligation to update or revise any
forward-looking statement for events or circumstances after the
date on which such statement is made except as required by
law.
Investor Relations:
Porter LeVay & Rose
Matthew Abenante, IRC, SVP
Phone: 212-564-4700
Email: MYOS@plrinvest.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/myos-rens-fortetropin-clinical-trial-results-to-be-presented-by-william-j-evans-phd-at-the-international-conference-on-frailty-and-sarcopenia-research-300961419.html
SOURCE MYOS RENS Technology Inc.